Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease
GastroHep · 2019
DOI: 10.1002/ygh2.331 ↗At a glance
Journal article in GastroHep, 2019. Written by Cristina Bezzio and 13 co-authors. Cited 3 times so far (Crossref); 30 references. Funded by: Merck Sharp and Dohme.
Abstract (original language)
Background
Italian physicians managing IBD patients seem to prescribe anti-TNFalpha agents less frequently than physicians in other countries.
Aims
To investigate reasons and situations that limit the use of these medications.
Methods
A questionnaire was distributed to 600 physicians attending IG-IBD events.
Results
Two hundred eighty physicians (46.7%) completed the questionnaire. Most physicians (76.2%) prescribed anti-TNFalpha every time one was needed, however, 12.6% were limited by budget, 8.1% lacked confidence, 2.2% lacked permission and 0.9% chose not to prescribe them. The limitations in using anti-TNFalpha were: fear of side effects (39.1%), costs (38.2%), administrative/bureaucratic limitations (8.0%) and lack of staff (6.2%). The main feared side effects include: opportunistic infection (45.7%), neoplasms (25.4%), allergic reactions (12.5%), reactivation of tuberculosis (7.3%) and onset of autoimmune disease (7.3%). Physicians younger than 45 years of age and with less than 15 years of clinical experience were more likely to prescribe anti-TNFalpha than older physicians (70.8% vs 57.1%; P = 0.022) than more experienced physicians (71.2% vs 58.9%; P = 0.033).
Conclusions
The apparent underuse of anti-TNFalpha in Italy can be attributed mainly to physicians’ fears of side effects, concerns about costs and scarce familiarity with these drugs. Addressing these barriers may lead to an improvement in the quality of assistance to IBD patients.
Funding
- Merck Sharp and Dohme
Cite
APA
Bezzio, C., Imperatore, N., Armuzzi, A., Rizzello, F., Manes, G., Bossa, F., Calabrese, E., Caprioli, F., Daperno, M., Mocciaro, F., Orlando, A., Papi, C., Rispo, A., & Saibeni, S. (2019). Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease. GastroHep. https://doi.org/10.1002/ygh2.331
Vancouver
Bezzio C, Imperatore N, Armuzzi A, Rizzello F, Manes G, Bossa F, et al. Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease. GastroHep. 2019. doi:10.1002/ygh2.331
BibTeX
@article{Bezzio2019,
author = {Bezzio, Cristina and Imperatore, Nicola and Armuzzi, Alessandro and Rizzello, Fernando and Manes, Gianpiero and Bossa, Fabrizio and Calabrese, Emma and Caprioli, Flavio and Daperno, Marco and Mocciaro, Filippo and Orlando, Ambrogio and Papi, Claudio and Rispo, Antonio and Saibeni, Simone},
title = {Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease},
journal = {GastroHep},
year = {2019},
doi = {10.1002/ygh2.331}
}
EUVIMED